Target Gene/Pathway Pathway / Gene
Search results
Showing 1 to 10 of 43 entries
| No. | KEGG GENES | KEGG PATHWAY | KEGG DRUG | DrugBank | Disease ID | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 |
PARP2
💬1. PARP2
| [2] Base excision repair Base excision repair, Apoptosis | Olaparib
Olaparib
💬1. PARP2
| Olaparib | [2] 86 86, 285 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2 |
CD52
💬2. CD52
| - | Alemtuzumab
Alemtuzumab
💬2. CD52
| Alemtuzumab | [22] 13 13, 15, 19, 20, 36, 43, 44, 46, 49, 51, 60, 62, 63, 65, 85, 96, 164, 234, 283, 284, 285, 326 💬2. CD52
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3 |
PARP1
💬3. PARP1
| [5] Base excision repair Base excision repair, NF-kappa B signaling pathway, Apoptosis, Necroptosis, Diabetic cardiomyopathy [5] Base excision repair, NF-kappa B signaling pathway, Apoptosis, Necroptosis, Diabetic cardiomyopa ... | Olaparib
Olaparib
💬3. PARP1
| Olaparib | [2] 86 86, 285 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 4 |
CSF2RA
💬4. CSF2RA
| [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer [4] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, ... | Sargramostim
Sargramostim
💬4. CSF2RA
| Sargramostim | [7] 6 6, 28, 60, 62, 96, 229, 285 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 5 |
CSF3R
💬5. CSF3R
| [5] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer [5] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, ... | Filgrastim
Filgrastim
💬5. CSF3R
| Filgrastim | [35] 2 2, 6, 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬 [35] 2, 6, 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 6 ... 5. CSF3R
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 6 |
DHFR
💬6. DHFR
| [5] One carbon pool by folate One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance [5] One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, A ... | Methotrexate
Methotrexate
💬6. DHFR
| Methotrexate | [38] 11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬 [38] 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, ... 6. DHFR
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 7 |
DHFR2
💬7. DHFR2
| [5] One carbon pool by folate One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance [5] One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, A ... | Methotrexate
Methotrexate
💬7. DHFR2
| Methotrexate | [38] 11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬 [38] 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, ... 7. DHFR2
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 8 |
ESR1
💬8. ESR1
| [9] Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer [9] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone s ... | Danazol
Danazol
💬8. ESR1
| Danazol | [5] 60 60, 63, 64, 65, 285 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 9 |
NR3C1
💬9. NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | Methylprednisolone
Methylprednisolone
💬9. NR3C1
| Methylprednisolone | [46] 2 2, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬 [46] 2, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, ... 9. NR3C1
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 10 |
IMPDH1
💬10. IMPDH1
| [4] Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | Mycophenolate mofetil
Mycophenolate mofetil
💬10. IMPDH1
| Mycophenolate mofetil | [34] 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬 [34] 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, ... 10. IMPDH1
|